A phase 1, open-label, dose-escalation study of selinexor plus ruxolitinib in patients with treatment-naive myelofibrosis.

被引：0
|
作者：
Ali, Haris
Kishtagari, Ashwin
Maher, Keri Renee
Mohan, Sanjay
Mazumder, Amitabha
Chamoun, Kamal
Karasik, Igor
Sbar, Eric
Dugon, Laura
Tamir, Sharon
Wang, Xulong
Prchal, Josef T.
Tantravahi, Srinivas Kiran
机构：
[1] City Hope Natl Med Ctr, Duarte, CA USA
[2] Mt Sinai St Lukes Roosevelt Hosp, New York, NY USA
[3] VCU Massey Canc Ctr, Richmond, VA USA
[4] Vanderbilt Univ Sch Med, Nashville, TN USA
[5] Oncol Inst Hope Innovat, Tampa, FL USA
[6] Karyopharm Therapeutics Inc, Newton, MA USA
[7] Karyopharm Therapeut, Newton, MA USA
[8] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[9] Univ Utah Huntsman Canc Inst, Salt Lake City, UT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7060
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A Phase 1, open-label, dose-escalation study of selinexor plus ruxolitinib in patients with treatment-naive myelofibrosis
    Ali, Haris
    Kishtagari, Ashwin
    Maher, Keri
    Mohan, Sanjay
    Ansaldo, Karen
    Wang, Xulong
    Chamoun, Kamal
    Prchal, Josef T.
    Tantravahi, Srinivas K.
    CANCER RESEARCH, 2023, 83 (08)
  • [2] A Phase 1, Open-Label, Dose-Escalation Study of Selinexor Plus Ruxolitinib in Patients with Treatment-Naive Myelofibrosis
    Ali, Haris
    Kishtagari, Ashwin
    Maher, Keri
    Mohan, Sanjay R.
    Ansaldo, Karen
    Wang, Xulong
    Chamoun, Kamal
    Prchal, Josef T.
    Tantravahi, Srinivas K.
    BLOOD, 2022, 140 : 3986 - 3987
  • [3] A phase 1b, dose-finding study of ruxolitinib plus panobinostat in patients with myelofibrosis.
    Heidel, Florian
    Ribrag, Vincent
    Vannucchi, Alessandro M.
    Kiladjian, Jean-Jacques
    Passamonti, Francesco
    Hayat, Amjad
    Conneally, Eibhlin
    Kindler, Thomas
    Martino, Bruno
    Lipka, Daniel B.
    Acharyya, Suddhasatta
    Binlich, Florence
    Liu, Tracy
    Mu, Song
    Harrison, Claire N.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in JAKi-naive myelofibrosis.
    Mascarenhas, John
    Maher, Keri Renee
    Rampal, Raajit
    Bose, Prithviraj
    Podoltsev, Nikolai Alexandrovich
    Hong, Junshik
    Wang, Xulong
    Kye, Steve
    Harrison, Claire
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis
    Verstovsek, S.
    Talpaz, M.
    Ritchie, E.
    Wadleigh, M.
    Odenike, O.
    Jamieson, C.
    Stein, B.
    Uno, T.
    Mesa, R. A.
    LEUKEMIA, 2017, 31 (02) : 393 - 402
  • [6] A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis
    S Verstovsek
    M Talpaz
    E Ritchie
    M Wadleigh
    O Odenike
    C Jamieson
    B Stein
    T Uno
    R A Mesa
    Leukemia, 2017, 31 : 393 - 402
  • [7] Open-label dose-escalation study of oral 1-octanol in patients with essential tremor
    Shill, HA
    Bushara, KO
    Mari, Z
    Reich, M
    Hallett, M
    NEUROLOGY, 2004, 62 (12) : 2320 - 2322
  • [8] Navitoclax plus ruxolitinib in JAK inhibitor-naive patients with myelofibrosis: Preliminary safety and efficacy in a multicenter, open-label phase 2 study.
    Passamonti, Francesco
    Foran, James M.
    Tandra, Anand
    De Stefano, Valerio
    Fox, Maria Laura
    Mattour, Ahmad Hatem
    McMullin, Mary Frances
    Perkins, Andrew
    Rodriguez-Macias, Gabriela
    Sibai, Hassan
    Qin, Qin Q.
    Potluri, Jalaja
    How, Jonathan B.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] A phase 1, open-label, dose-escalation study of pralatrexate incombination with bortezomib in patients with relapsed/refractory multiple myeloma
    Dunn, Tamara J.
    Dinner, Shira
    Price, Elizabeth
    Coutre, Steven E.
    Gotlib, Jason
    Hao, Ying
    Berube, Caroline
    Medeiros, Bruno C.
    Liedtke, Michaela
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 (02) : 253 - 259
  • [10] Sorafenib dose escalation in treatment-naive patients with metastatic renal cell carcinoma: a non-randomised, open-label, Phase 2b study
    Gore, Martin E.
    Jones, Robert J.
    Ravaud, Alain
    Kuczyk, Markus
    Demkow, Tomasz
    Bearz, Alessandra
    Shapiro, Joann
    Strauss, Uwe Phillip
    Porta, Camillo
    BJU INTERNATIONAL, 2017, 119 (06) : 846 - 853
12345